Dr. Sylvain MEYLAN

Combining a PhD in bioengineering with an MD and clinical training in infectious diseases, my group is interested in developing innovative approaches to address important clinical challenges within 2 areas of focus:

Highlights

Sepsis

Sepsis is a highly lethal clinical syndrome defined by a dysregulated host response to infection. Approximately 50 million annual cases of sepsis globally lead to 11 million deaths, accounting for 10-20% of global mortality. Despite 30 plus years of dedicated research, no specific therapy for the dysregulated immune responses of sepsis has emerged beyond supportive care and infection management. Data increasingly points to the heterogeneous nature of sepsis as the crux of this problem – one size does not fit all. Within CHUV and through collaborations, we study both the pathophysiologic underpinnings of sepsis and the application of personalized therapy for dysregulated host responses.

Antibiotics

Antimicrobial resistance is emerging as the major challenge of our time. Innovative approaches to reinforcing our antibiotic armamentarium are urgently needed. Along with our partners in Urology and at EPFL, we are working to use metabolic manipulation of pathogens to enhance the efficacy of our antibiotics in a translational approach.